NASDAQ:ALNA

Allena Pharmaceuticals Stock Forecast, Price & News

$0.95

-0.05 (-5.00 %)

(As of 07/29/2021 01:14 PM ET)

Add

Compare

Today's Range

$0.95

▼

$1.04

50-Day Range

$0.78

▼

$1.39

52-Week Range

$0.75

▼

$2.78

Volume117,376 shs

Average Volume2.10 million shs

Market Capitalization$54.81 million

P/E RatioN/A

Dividend YieldN/A

Beta2.18

30 days | 90 days | 365 days | Advanced Chart

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Short Interest Up 41.9% in June
July 18, 2021 | americanbankingnews.com

Allena Pharma Stock Under Pressure After Equity Raise Of $28M
July 14, 2021 | finance.yahoo.com

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Given Consensus Rating of "Buy" by Analysts
July 14, 2021 | americanbankingnews.com

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
July 14, 2021 | finance.yahoo.com

Allena Revises Interim Reloxaliase Analysis Targeted Now For Q1 2022; ALLN-346 Phase 2 Data On Track For End Of 2021
July 12, 2021 | benzinga.com

Allena Pharmaceuticals Provides Update on Clinical Development Programs
July 12, 2021 | finance.yahoo.com

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Expected to Post Earnings of -$0.20 Per Share
July 9, 2021 | americanbankingnews.com

Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 8, 2021 | finance.yahoo.com

Critical Review: Orchard Therapeutics (NASDAQ:ORTX) & Allena Pharmaceuticals (NASDAQ:ALNA)
July 5, 2021 | americanbankingnews.com

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease
June 8, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALNA
Previous Symbol
CUSIPN/A
CIK1624658
Webwww.allenapharma.com
Phone617-467-4577
Employees45
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.44 per share
Price / Book2.16

Profitability

EPS (Most Recent Fiscal Year)($1.01)
Net Income$-32,850,000.00
Net MarginsN/A
Return on Equity-178.62%
Return on Assets-105.06%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares57,690,000
Market Cap$54.81 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.71 out of 5 stars

Medical Sector

664th out of 2,214 stocks

Biological Products, Except Diagnostic Industry

105th out of 213 stocks

3.5 Analyst's Opinion

Consensus Rating
Allena Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.50, Allena Pharmaceuticals has a forecasted upside of 1,110.5% from its current price of $0.95.
Amount of Analyst Coverage
Allena Pharmaceuticals has received no research coverage in the past 90 days.

3.4 Community Rank

Outperform Votes
Allena Pharmaceuticals has received 234 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Allena Pharmaceuticals has received 108 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Allena Pharmaceuticals has received 68.42% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Allena Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Allena Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allena Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,989.00 in company stock.
Percentage Held by Insiders
Only 10.10% of the stock of Allena Pharmaceuticals is held by insiders.
Percentage Held by Institutions
35.29% of the stock of Allena Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Allena Pharmaceuticals are expected to decrease in the coming year, from ($0.83) to ($0.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allena Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allena Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allena Pharmaceuticals has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

Is Allena Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Allena Pharmaceuticals stock.
View analyst ratings for Allena Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Allena Pharmaceuticals?

Wall Street analysts have given Allena Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allena Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Allena Pharmaceuticals?

Allena Pharmaceuticals saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 1,290,000 shares, a decrease of 13.4% from the June 30th total of 1,490,000 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.6% of the company's shares are short sold.
View Allena Pharmaceuticals' Short Interest.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Allena Pharmaceuticals.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its quarterly earnings results on Monday, May, 10th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01.
View Allena Pharmaceuticals' earnings history.

How has Allena Pharmaceuticals' stock price been impacted by COVID-19?

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALNA stock has decreased by 23.7% and is now trading at $0.9610.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ALNA?

3 Wall Street analysts have issued 12-month target prices for Allena Pharmaceuticals' stock. Their forecasts range from $5.00 to $18.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $11.50 in the next twelve months. This suggests a possible upside of 1,096.7% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:

Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 68, Pay $70k)
Dr. Louis Brenner, Pres, CEO & Director (Age 51, Pay $823.22k)
Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 56)
Dr. Richard D. Katz, CFO, Principal Financial Officer & Principal Accounting Officer (Age 57)
Mr. Geoffrey A. Swire, Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer (Age 49)
Mr. Hugh Wight, Sr. VP of Technical Operations
Ms. Alicja Januszewicz Ph.D., VP of People & Culture
Dr. David J. Clark, Chief Medical Officer (Age 56)
Mr. Stephen Yu, Sr. VP of Corp. Quality

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Allena Pharmaceuticals' key competitors?

Some companies that are related to Allena Pharmaceuticals include Immatics (IMTX), ADMA Biologics (ADMA), Cardiff Oncology (CRDF), Cabaletta Bio (CABA), Elevation Oncology (ELEV), Miromatrix Medical (MIRO), Genfit (GNFT), Fennec Pharmaceuticals (FENC), Freeline Therapeutics (FRLN), CASI Pharmaceuticals (CASI), Applied Genetic Technologies (AGTC), Ayala Pharmaceuticals (AYLA), X4 Pharmaceuticals (XFOR), Champions Oncology (CSBR) and Axcella Health (AXLA).
View all of ALNA's competitors.

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $0.96.

How much money does Allena Pharmaceuticals make?

Allena Pharmaceuticals has a market capitalization of $55.44 million. The company earns $-32,850,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Allena Pharmaceuticals have?

Allena Pharmaceuticals employs 45 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

Where are Allena Pharmaceuticals' headquarters?

Allena Pharmaceuticals is headquartered at ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here